Pancreatic ductal adenocarcinoma (PDA) is the most common form of pancreatic cancer. PDA cells are characterized by dysregulated metabolic programs that facilitate growth and resistance to oxidative stress. Among these programs, the metabolic pathway through GOT1 is utilized by PDA to support cellular redox homeostasis. To date, selective small molecule inhibitors of GOT1 that could serve as starting points for the development of new therapies for pancreatic cancer do not exist. Thus, we performed a high-throughput small molecule in vitro screen against GOT1.

Do you have a question or comment for the presenter? Let us know.